Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + paclitaxel + bevacizumab
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (afatinib), Intravenous (paclitaxel, Bevacizumab)
01
Overview
**Afatinib + paclitaxel + bevacizumab** is an investigational combination therapy composed of three distinct agents used in oncology clinical trials for advanced solid tumors, including non-small cell lung cancer (NSCLC)[1][2]. **Afatinib** is an irreversible inhibitor of the ErbB family of tyrosine kinases (including EGFR/HER1, HER2, and HER4), blocking downstream pro-proliferative and anti-apoptotic signaling. **Paclitaxel** is a chemotherapeutic agent that promotes microtubule polymerization and stabilization, inhibiting cell division. **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis[1]. This combination is designed to leverage complementary mechanisms: targeted receptor blockade by afatinib, cytotoxic cytoskeleton disruption by paclitaxel, and anti-angiogenic VEGF inhibition by bevacizumab. Phase I studies have established a recommended dosing regimen and evaluated safety, pharmacokinetics, and anti-tumor activity, with observed partial responses and stable disease in a majority of advanced solid tumor patients[1][2].
- Brand names
- afatinib + paclitaxel + bevacizumab
- Other names
- afatinib + paclitaxel + bevacizumab
02
Targets
ERBB4 (Erb-b2 receptor tyrosine kinase 4)VEGFA (Vascular endothelial growth factor A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on afatinib + paclitaxel + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + paclitaxel + bevacizumab.